Condition
T Cell Lymphoblastic Lymphoma
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Unknown1
Recruiting1
Terminated1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07300683Phase 1Recruiting
Anti-CCR9 CAR T Cells for T Cell Leukaemia/Lymphoma
NCT05038644Phase 1Terminated
XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia
NCT05554575Phase 1UnknownPrimary
Chimeric Antigen Receptor T-Cell (CAR-T) Cells in Patients With R/R T-LBL
Showing all 3 trials